JAK2 inhibitors: are they the solution?

Abstract excerpt

The discovery of the JAK2V617F mutation in patients with Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN) started the era of targeted therapy for these diseases. Until now, patients had few treatment options available, which usually were restricted to hydroxyurea, interferon preparations, and chemotherapy in more aggressive cases. JAK2 inhibitors have been developed over the past 5 years, and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Janus Kinase 2
• Share to Molecular Targeted Therapy
• Share to Myeloproliferative Disorders